🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you IndiaBioscience.org for sharing my experience on getting the NARSAD grant from BBRFoundation during my postdoctoral work.

We’re excited to welcome Dr. Dhananjay Huilgol to the BRIC-NBRC team as Scientist-IV! His research focuses on cellular and gene mechanisms driving neuronal differentiation and diversity, with insights into cortical evolution and neurodevelopmental disorders.

I'm thrilled to share my lab's first manuscript identifying that paraspeckle protein NONO regulates active chromatin through allosteric activation of NSD1 on BioRxiv: biorxiv.org/content/10.110… As a baby PI who started in a literally empty building, we weren't able to do biochem

We report a new role for HIF in the regulation of endogenous retroviruses! It was a big collaborative effort to explore the HIF-mediated transcription, expression, and HLA presentation of ERVs in kidney cancer and leveraging them for immunotherapy cell.com/cell/fulltext/…

I am excited to announce the launch of the Slabicki Lab at the Krantz Family Center for Cancer Research within the Mass General Cancer Center and the Cancer Program at the Broad Institute of MIT and Harvard! 🔗 Learn more: slabicki-lab.org

New study just out from KaelinLab in Cancer Discovery elucidating more about the dependence of #kidneycancer tumor cells on HIF2, implicating Cyclin D1 activity in resistance mechanisms to HIF2-targeted therapy aacrjournals.org/cancerdiscover…

We report that Cyclin D1 is an important direct target of HIF2 that drives the proliferation of ccRCC. Our findings further support the notion of combining HIF2 and CDK4/6 inhibitors to enhance antitumor activities. Congrats to Nitin Shirole and the team!

We had a great time celebrating the group's many accomplishments!

🌟Insightful, data-rich, and clinically grounded presentation by Cris at #IKCSEU25 Kidney Cancer OncoAlert 🟠 Belzutifan shows 49% ORR and 98% clinical benefit in VHL-associated RCC 🟠 Strong responses also seen in pancreatic (77%) and neuroendocrine tumors (94%) 🟠

I have a baby lab! We have some exciting questions on developmental neuroscience. Please apply if interested in joining me

#ASCO25 Excellent summary slide of trials of HIF-2α inhibitor therapy in refractory RCC 📷Tian Zhang, MD, MHS UroToday.com

In 2023, the FDA approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD, KaelinLab. Now, Toni Choueiri, MD, director of Dana-Farber Lank Center for Genitourinary Oncology, and team are working to expand its clinical use. bit.ly/3GNeb9D